Alterity Therapeutics Ltd. Sponsored ADR Forecast, price target & analysts
Alterity Therapeutics Ltd. Sponsored ADR Target price 2025 - Analyst rating & recommendation
Alterity Therapeutics Ltd. Sponsored ADR Price Target
| Target Price | $12.00 |
| Price | $5.02 |
| Potential |
139.04%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Alterity Therapeutics Ltd. Sponsored ADR price target 2026.
The average Alterity Therapeutics Ltd. Sponsored ADR target price is $12.00.
This is
139.04%
register free of charge
|
|
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Alterity Therapeutics Ltd. Sponsored ADR stock has an average upside potential 2026 of
139.04%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.17 | 1.12 |
| 1,600.00% | 556.47% | |
| Net Margin | -7,305.88% | -390,921.04% |
| 91.85% | 5,250.77% |
1 Analyst has issued a sales forecast Alterity Therapeutics Ltd. Sponsored ADR 2025 . The average Alterity Therapeutics Ltd. Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Alterity Therapeutics Ltd. Sponsored ADR 2025 . The average Alterity Therapeutics Ltd. Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Jun '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.00 | -0.82 |
| P/E | negative | |
| EV/Sales | 61.20 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
